Optionele productanalyse
Met uw toestemming gebruiken we privacyvriendelijke, beperkte analyses om te begrijpen welke onderzoeksroutes werken. We gebruiken geen advertentietrackers of sessieopnamen. U kunt deze keuze wijzigen in Voorkeuren. Lees het Privacybeleid.
Merck & Co., Inc.'s published Hold conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $370.9B | |
|---|---|---|
| Revenue (ttm) | 66.6B | |
| Net income (ttm) | 3.2B | |
| EPS (ttm) | $1.27 | |
| Shares out | 2.5B | |
| P/E (trailing) | 110.8x | |
| P/E (forward) | 15.7x | |
| Dividend | $3.40 (2.42%) | |
| Volume | 6,404,220 | |
| Beta | 0.22 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $48.70B | $59.28B | $60.12B | $64.17B | $65.01B | +7.5% |
| Gross profit | $35.08B | $41.87B | $43.99B | $48.98B | $46.73B | +7.4% |
| Operating income | $14.69B | $17.41B | $3.04B | $21.21B | $22.42B | +11.2% |
| Net income | $13.05B | $14.52B | $365.0M | $17.12B | $18.25B | +8.8% |
| EPS (diluted) | $5.14 | $5.71 | $0.14 | $6.74 | $7.28 | +9.1% |
| EBITDA | $17.90B | $21.32B | $6.91B | $25.71B | $28.26B | +12.1% |
| R&D | $12.25B | $13.55B | $30.53B | $17.94B | $15.79B | +6.6% |
| SG&A | $9.63B | $10.04B | $10.50B | $10.82B | $10.73B | +2.7% |
Recent company headlines from major financial publishers.
Revenue recovery continues, margins normalize and per-share results receive modest support from a lower share count. Later growth remains measured rather than accelerating.
Upside persists if growth and margins last beyond the rebound. It fades if stronger results require more investment or debt than operating cash can fund.
| Ke ↓ / g → | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% |
|---|---|---|---|---|---|
| 4.6% | $176 | $195 | $223 | $268 | $352 |
| 5.6% | $146 | $156 | $169 | $187 | $214 |
| 6.6% | $127 | $133 | $141 | $150 | $163 |
| 7.6% | $114 | $118 | $122 | $128 | $135 |
| 8.6% | $104 | $107 | $110 | $114 | $118 |
Upcoming earnings date and setup when available.
De rating die de gepubliceerde researcheditie van elke maand droeg. Een rating vergelijkt de koers op de analysedatum met de fair value; het is geen overzicht van of de inschatting juist bleek.
| Jaar | jan | feb | mrt | apr | mei | jun | jul | aug | sep | okt | nov | dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
